Home >> Blog >> Mono Pharmacare Limited IPO - Review, Valuation & Today GMP
Mono Pharmacare Limited IPO - Review, Valuation & Today GMP
Table of Contents
Mono Pharmacare Limited - Complete Overview
Established in 1994, Mono Pharmacare Limited operates in the pharmaceutical sector, primarily focusing on pharmaceutical product marketing and distribution.
The company works with various contract manufacturers to produce its products and sells those items under its brand "DLS Export". The company acquired DLS Export in 2022 for an aggregate amount of Rs.609 lakhs.
The company's product range encompasses Health Care products, Antibiotics, Cough and Cold Anti-Allergic medications, Antifungal treatments, Nutraceuticals, Analgesics, Antipyretics, Antacids, Antiemetics, Cardiac-Diabetic medicines, as well as skincare and cosmetic offerings.
As of February 28, 2023, the company maintains connections with 168 pharmaceutical enterprises and engages with a diverse clientele of 3,036 customers and vendors. This client mix includes both retail pharmacy stores and wholesalers.
What does the company do?
Mono Pharmacare Limited operates in the pharmaceutical sector, primarily focusing on pharmaceutical product marketing and distribution.
Company Products
The company's product range encompasses Health Care products, Antibiotics, Cough and Cold Anti-Allergic medications, Antifungal treatments, Nutraceuticals, Analgesics, Antipyretics, Antacids, Antiemetics, Cardiac-Diabetic medicines, as well as skincare and cosmetic offerings.
IPO Overview
The upcoming SME IPO of Mono Pharmacare Limited is set to launch on the NSE SME platform. The Mono Pharmacare IPO date is scheduled from August 28 to August 30, 2023. The Mono Pharmacare IPO price is set between Rs.26 to Rs.28 per share.
Anticipated to be listed on September 8, 2023, the IPO holds a total issue size of Rs.14.84 Crores. Within this total issue, the company has allocated 45% to retail investors, another 45% to non-institutional investors, and the remaining 10% to institutional investors.
Mono Pharmacare Limited IPO timetable (Tentative)
EVENTS |
DATE |
IPO Opening Date |
28 August 2023 |
IPO Closing Date |
30 August 2023 |
IPO Allotment Date |
4 September 2023 |
Refund initiation |
5 September 2023 |
IPO Listing Date |
7 September 2023 |
Mono Pharmacare Limited IPO Details
IPO Opening & Closing Date |
28 August to 30 August 2023 |
Face Value |
Rs. 10 per share |
Issue Price |
Rs. 26 to Rs. 28 per share |
Lot Size |
4000 Shares |
Price of 1 Lot |
Rs. 112,000 |
Issue Size |
5,500,000 Shares (aggregating up to Rs.14.84 Cr) |
Offer for Sale |
NA |
Fresh Issue |
5,500,000 Shares (aggregating up to Rs.14.84 Cr) |
Listing at |
NSE SME |
Issue Type |
Book Built Issue IPO |
Registrar |
Bigshare Services Pvt. Ltd. |
Mono Pharmacare Limited IPO Lot Details
Minimum Lot Investment (Retail) |
1 Lot |
Maximum Lot Investment (Retail) |
1 Lot |
Minimum Lot Investment (HNI) |
2 Lot |
Mono Pharmacare Limited IPO Reservation
Institutional Share Portion |
10% |
Non-Institutional Share Portion |
45% |
Retail Share Portion |
45% |
Company Financial
Amount in Lakhs
Period |
FY 20 |
FY 21 |
FY 22 |
Total Assets |
871.70 |
1122.46 |
1438.31 |
Total Revenue |
1168.90 |
2837.83 |
3710.27 |
PAT |
1.99 |
9.51 |
35.09 |
Net Worth |
201.92 |
369.58 |
427.57 |
Reserve & Surplus |
633.46 |
608.03 |
643.93 |
Total Borrowings |
1608.65 |
1795.46 |
1588.99 |
Contribution of the top 10 customers towards the revenue from operations:
Amount in Lakhs
Particulars |
Revenue from operations |
Revenue contribution of our top 10 customers |
FY 23 |
4,585.83 |
3,304.88 |
FY 22 |
3,698.30 |
2,853.59 |
FY 21 |
2,826.61 |
2,422.87 |
Objective of the Issue
The company intends to employ the funds to achieve the following objectives:
- Fulfilling working capital needs.
- Addressing general corporate purposes.
- Covering the expenses related to the issue.
Promoters and Management of Mono Pharmacare Limited
Panilam Lakhatariya and Supal Lakhatariya are the key Promoters of our Company.
Pre-issue Promoters Holding |
81.02% |
Post-issue Promoters Holding |
|
Peer Comparison
The following are the peers of the company as per the Mono Pharmacare DRHP.
Company Name |
Revenue from operations (Rs. in Lakhs) |
Diluted EPS (Rs.) |
P/E Ratio |
Mono Pharmacare Limited |
5,847.64 |
1.99 |
- |
Chandra Bhagat Pharma Limited |
11,967.22 |
1.20 |
112.50 |
IPO's Valuations
Mono Pharmacare Limited's upcoming IPO is set to launch soon within a price range of Rs.26 to Rs.28 per share. The company currently maintains an EPS of Rs.1.99. Although the company has not specified the PE ratio, utilizing the upper band of the IPO price range indicates a PE ratio of approximately 14.
Dividend Policy
The company has not distributed dividends in the past, and there is no assurance of future dividend payments as well.
IPO's Strengths
- The company is led by experienced promoters and a management team possessing industry expertise and a proven track record.
- The business model is designed to be asset-light, and the company offers competitive products.
- The company's business model is capable of scalability.
- The company boasts an extensive and varied selection of product offerings.
IPO Weaknesses
- The company relies on third parties for manufacturing products.
- The company operates within a business model characterized by high volume and low margins.
- The major portion of the company's revenue is contributed by its top ten customers.
- The company is currently facing legal proceedings.
- As of March 31, 2023, the company holds unsecured loans amounting to ?1,584.45 lakhs, which the lenders can demand repayment of at any time.
- The Promoters and Directors possess interests in entities engaged in similar businesses, potentially leading to conflicts of interest.
- The company is obligated to secure and renew various registrations, licenses, approvals, NoCs, and permits.
IPO GMP Today
Mono Pharmacare limited IPO GMP is not yet available.
Conclusion
The upcoming IPO of Mono Pharmacare Limited offers investors a chance to participate in the pharmaceutical sector. While the company's business model is scalable, it operates within a high volume - low margin business framework. Potential investors might find this IPO worth considering; nevertheless, it is recommended to thoroughly analyze all factors before investing funds in this offering.
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company Click Here to Download the RHP
Thank You for reading this blog.
Hope you loved the IPO analysis.
Please Comment Below with your feedback because Your feedback motivates us to deliver more such content.
Follow MUKUL AGRAWAL for the latest IPO news and reviews. You can connect with us on social media platforms like Twitter, Facebook, and Instagram. You can also subscribe to our YouTube Channel for the latest videos of the stock market.
Frequently Asked Questions
Discover insights into the upcoming Mono Pharmacare Limited IPO, offering investors a chance to be a part of the pharmaceutical sector's growth journey.
Learn the step-by-step process to participate in the IPO and seize the opportunity to invest in Mono Pharmacare Limited.
Explore the unique qualities and competitive advantages that make Mono Pharmacare Limited a promising investment choice.
Gain insights into the growth prospects and potential returns that investing in Mono Pharmacare Limited's IPO might offer.
Understand how Mono Pharmacare Limited is driving healthcare innovation and its impact on the industry.